AKRO•benzinga•
Akero Therapeutics Said It Has Completed Enrollment In The Double-blind Portion Of The Phase 3 SYNCHRONY Real-world Study Of Efruxifermin (EFX) For Metabolic Dysfunction-Associated Steatohepatits Or Steatotic Liver Disease, Results Expected In 1H Of 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga